Business Description
IRulya Therapeutics, formerly Quince Therapeutics, is a biotechnology company founded in 2012 and based in New Haven, Connecticut, that develops treatments for rare and serious diseases. Its most advanced program is eDSP, currently in Phase 3 clinical trials for a rare inherited childhood brain disease called ataxia-telangiectasia, which progressively damages the nervous system and weakens the immune system. The company's proprietary AIDE platform works by loading medication directly into a patient's own red blood cells using an automated system, offering a novel way to deliver drugs more precisely. IRulya changed its name in October 2026 as part of a broader repositioning of its mission and identity.
